Shanghai - Delayed Quote CNY

Wuhan Keqian Biology Co.,Ltd (688526.SS)

Compare
13.79 -0.71 (-4.90%)
At close: November 22 at 3:00 PM GMT+8
Loading Chart for 688526.SS
DELL
  • Previous Close 14.50
  • Open 14.50
  • Bid 13.79 x --
  • Ask 13.80 x --
  • Day's Range 13.70 - 14.50
  • 52 Week Range 11.00 - 20.61
  • Volume 2,311,822
  • Avg. Volume 2,668,838
  • Market Cap (intraday) 6.428B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 21.55
  • EPS (TTM) 0.64
  • Earnings Date --
  • Forward Dividend & Yield 0.43 (3.12%)
  • Ex-Dividend Date May 22, 2024
  • 1y Target Est --

Wuhan Keqian Biology Co.,Ltd focuses on the research and development, production, sales, and animal epidemic prevention technical services of veterinary biological products in China. It offers vaccines for swine, poultry, and pets, as well as diagnostic reagents. The company was incorporated in 2001 and is based in Wuhan, China.

www.kqbio.com

923

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688526.SS

View More

Performance Overview: 688526.SS

Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

688526.SS
30.80%
SSE Composite Index
9.82%

1-Year Return

688526.SS
28.44%
SSE Composite Index
6.49%

3-Year Return

688526.SS
45.51%
SSE Composite Index
8.23%

5-Year Return

688526.SS
53.25%
SSE Composite Index
0.22%

Compare To: 688526.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688526.SS

View More

Valuation Measures

Annual
As of 11/22/2024
  • Market Cap

    6.43B

  • Enterprise Value

    5.43B

  • Trailing P/E

    21.55

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.13

  • Price/Book (mrq)

    1.67

  • Enterprise Value/Revenue

    6.01

  • Enterprise Value/EBITDA

    15.55

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    33.16%

  • Return on Assets (ttm)

    3.30%

  • Return on Equity (ttm)

    7.83%

  • Revenue (ttm)

    902.14M

  • Net Income Avi to Common (ttm)

    299.11M

  • Diluted EPS (ttm)

    0.64

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.07B

  • Total Debt/Equity (mrq)

    1.65%

  • Levered Free Cash Flow (ttm)

    119.37M

Research Analysis: 688526.SS

View More

Company Insights: 688526.SS

Research Reports: 688526.SS

View More

People Also Watch